NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
TMI is developing the POINT-GUARD, the first and only cerebral embolic protection device with dynamic Double-Edge Sealing. The seal adapts and conforms to complex...
Hall Venture Partners is located at a state-of-the-art Hall Labs innovation campus in Provo, Utah. Hall Venture Partners was established to address the growing...
Matt Patsky is CEO and Lead Portfolio Manager of the Trillium ESG Global Equity strategy and Portfolio Manager of the Trillium Sustainable Opportunities strategy....
